JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Real-world outcomes for primary and secondary central nervous system lymphoma
Abstract
Aims: Central nervous system lymphoma (CNSL) is a rare and aggressive subtype of extranodal non-Hodgkin lymphoma, including primary and secondary forms. Despite advances in treatment, outcomes remain suboptimal. In this study, real-world treatment outcomes and prognostic factors in CNSL patients were evaluated.
Methods: The study should be described, including selection criteria, design (randomized, retrospective/prospective, etc.), and statistical methods applied, if applicable.
Results: The median age was 53 years, and 62.5% of patients had primary CNSL. High-dose methotrexate-based regimens yielded high response rates, with overall response rates of 92.3% for the MATRix regimen and 86.7% for the modified Bonn protocol. Autologous stem cell transplantation (ASCT) was associated with an improvement in complete/unconfirmed complete response rates (52.5% pre-ASCT vs. 65% post-ASCT). At a median follow-up of 1124 days, the overall survival and progression-free survival rates were 52.5% and 35%, respectively. Relapse occurred in 50% of patients. Prognostic scoring systems demonstrated limited applicability due to missing data and the small sample size.
Conclusion: High-dose methotrexate-based regimens followed by ASCT remain effective in CNSL; however, relapse rates remain high. Improved prognostic models and novel therapies are needed.

Keywords : Central nervous system lymphoma, primary central nervous system lymphoma, methotrexate-based therapy, autologous stem cell transplantation

Download Article
Ethical Statement

<p>This study was approved by the Clinical Researches Ethics Committee of Gazi University (Date: 10.10.2022, Decision No: 730).</p>

Informed Consent

<p>This retrospective study used pre-existing anonymized patient data. No additional intervention was performed, and there was no direct patient contact. The study was approved by the Ethics Committee, and the requirement for written informed consent was waived by the ethics committee.</p>

Author Contributions

<p>Concept: BBD, MY; Design: BBD, ZN&Ouml;, ZAY, MY; Control: BBD, MY; Materials: BBD, ZN&Ouml;, ZAY, MY; Data Collection and/or Processing: BBD, ZN&Ouml;, ZAY, MY; Analysis and/or Interpretation: BBD; Literature Review: BBD, MY; Writing the Article: BBD; Critical Review: BBD, ZN&Ouml;, ZAY, MY.</p>

Conflict of Interest

<p>The authors declare no conflicts of interest related to this study.</p>

Financial Disclosure

<p>The authors received no financial support for the conduct or publication of this research.</p>


1. Correia CE, Schaff LR, Grommes C. Central nervous system lymphoma: approach to diagnosis and treatment. Cancer J. 2020;26(3):241-252. doi:10.1097/PPO.0000000000000449
2. Ferreri AJM, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9(1):29. doi:10.1038/s41572-023-00439-0
3. Radke J, Ishaque N, Koll R, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13(1):2558. doi:10.1038/s41467-022-30050-y
4. Fleming M, Huang Y, Dotson E, et al. Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol. 2022;13:20406207221112900. doi:10.1177/20406207221112900
5. Kasenda B, Ferreri AJM, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305-1313. doi:10.1093/annonc/mdv076
6. Alcantara M, Chevrier M, Jardin F, et al. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol. 2024;17(1):86. doi:10.1186/s13045-024-01606-w
7. Liu CJ, Lin SY, Yang CF, et al. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med. 2020;9(6):2134-2145. doi:10.1002/cam4.2872
8. Abrey LE, Batchelor TT, Ferreri AJM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043. doi:10.1200/JCO.2005.13.524
9. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068. doi:10.1200/JCO.2013.54.8800
10. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510-e523. doi:10.1016/S2352-3026(17)30174-6
11. Zeyen T, Weller J, Schneider M, et al. High-dose MTX-based polychemotherapy for primary CNS lymphoma in younger patients: long-term efficacy of the modified Bonn protocol. Neuro Oncol Adv. 2025;7(1):vdaf005. doi:10.1093/noajnl/vdaf005
12. Houillier C, Dureau S, Taillandier L, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J Clin Oncol. 2022;40(32):3692-3698. doi:10.1200/JCO.22.00491
13. Khwaja J, Kirkwood AA, Isbell LK, et al. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica. 2022;108(3):882-888. doi:10.3324/haematol.2022.281640
14. Gurusamy VM, Divakar SR, Chandramouli SH, et al. The role of radiotherapy in newly diagnosed primary CNS lymphoma: a descriptive review and a pragmatic approach to clinical practice. Clin Transl Radiat Oncol. 2023;39:100559. doi:10.1016/j.ctro.2022.12.002
15. Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20
16. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410-2418. doi:10.1200/JCO.2017.72.7602
17. Schaff LR, Pentsova E, Malani R, et al. Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma. Neuro Oncol. 2026;28(5):1277-1285. doi:10.1093/neuonc/noag011
18. Losi G, Mussetti A, Peña M, Lopez-Pereira P, Sureda A, Novelli S. Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas. Bone Marrow Transplant. 2025;60(3):259-269. doi:10.1038/s41409-024-02496-9
19. Mohammed Saleh M, Rasheed W, Alhayli S, Alshaibani A, Aljurf M, El Fakih R. Programmed death inhibitors in CNS B-cell lymphoma: a literature review. Blood Rev. 2025;74:101321. doi:10.1016/j.blre.2025.101321
20. Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23(1):122-133. doi:10.1093/neuonc/noaa145
21. Wang J, Cheng HE, Sun Y, et al. Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis. Front Pharmacol. 2025;16:1559056. doi:10.3389/fphar.2025.1559056
Article available in :
Volume 4, Issue 4, 2026
Page : 120-124
https://doi.org/10.51271/JCHOR-0094
Article Information
Received : 16 Apr 2026
Accepted : 08 Jul 2026
Published : 13 Nov 2026
Corresponding Author :

Başak Bostankolu Değirmenci: Department of Hematology, Ankara Atatürk Sanatorium Training and Research Hospital, Ankara, Turkiye

[email protected]
Citation : Bostankolu Değirmenci B, Özkurt ZN, Yeğin ZA, Yağcı M. Real-world outcomes for primary and secondary central nervous system lymphoma. J Curr Hematol Oncol Res. 2026;4(4):120-124. doi:10.51271/JCHOR-0094

Read: 7
Download : 3
Cited: 0
_Footer